secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002673
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam dosed first SCD patient, submitted CTA for AATD, cash $1.2B into 2027
--------------------------------------------------------------------------

- First patient dosed in BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease; initial data expected H2 2024.
- CTA submitted for BEAM-302 in alpha-1 antitrypsin deficiency; trial initiation planned H1 2024.
- IND for BEAM-301 in glycogen storage disease 1a on track for H1 2024.
- Estimated cash, cash equivalents and marketable securities of $1.2B as of Dec 31, 2023, funding operations into 2027.
- BEAM-201 CAR-T trial enrollment ongoing; initial clinical dataset expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024002673/0000950170-24-002673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024002673/beam-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer